Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...

The US Food and Drug Administration has approved the first once-monthly subcutaneous injection of risperidone (Perseris, Indivior) for the treatment of schizophrenia in adults. Perseris uses an ...

What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 disorder. For anyone managing bipolar 1 disorder, staying consistent with daily ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...

The FDA has approved Risperdal Consta (risperidone long-acting injection, from Janssen) for use as monotherapy or as adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of adverse events were similar in both dosing ...

About Risperidone Extended-Release Injectable Suspension for Subcutaneous Use The extended-release subcutaneous risperidone injection is an investigational once-monthly or once-every-two-months ...

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...